China Suspends Two Leukemia Drugs (China)
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration has announced it is suspending the sale of two drugs used to treat leukemia and rheumatoid arthritis. The drugs, methotrexate and cytarabin hydrochloride, became the subject of scrutiny after the release of information by the National Center for ADR Monitoring. Patients taking the two drugs experienced adverse side effects including impaired leg movement and urine retention. The Chinese results are only the latest of 12,500 accounts of undesirable reactions to methotrexate. (Click here for more - May Require Free Registration